Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Yesterday, March 23, 2016, 65 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $249.20 to $12,675,000.00.

Highlighted Stocks Traded by Insiders:

Antares Pharma (ATRS) - FREE Research Report

Graham Peter J, who is SVP General Counsel, Secretary at Antares Pharma, bought 20,000 shares at $0.77 on March 23, 2016. Following this transaction, the SVP General Counsel, Secretary owned 20,000 shares meaning that the stake was boosted by 100% with the 20,000-share transaction.

The shares most recently traded at $0.71, down $0.06, or 8.45% since the insider transaction. Historical insider transactions for Antares Pharma go as follows:

  • 4-Week # shares bought: 525,000
  • 4-Week # shares sold: 23,500
  • 12-Week # shares bought: 525,000
  • 12-Week # shares sold: 23,500
  • 24-Week # shares bought: 525,000
  • 24-Week # shares sold: 23,500

The average volume for Antares Pharma has been 1.0 million shares per day over the past 30 days. Antares Pharma has a market cap of $119.2 million and is part of the health care sector and health services industry. Shares are down 39.67% year-to-date as of the close of trading on Wednesday.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. Currently, there are 4 analysts who rate Antares Pharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATRS - FREE

TheStreet Quant Ratings rates Antares Pharma as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Antares Pharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Core Molding Technologies (CMT) - FREE Research Report

Ringling William, who is Vice President of Operations at Core Molding Technologies, bought 2,900 shares at $12.08 on March 23, 2016. Following this transaction, the Vice President of Operations owned 9,177 shares meaning that the stake was boosted by 46.2% with the 2,900-share transaction.

The shares most recently traded at $12.10, up $0.02, or 0.17% since the insider transaction. Historical insider transactions for Core Molding Technologies go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 5,957
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 5,957
  • 24-Week # shares bought: 7,300
  • 24-Week # shares sold: 5,957

The average volume for Core Molding Technologies has been 24,900 shares per day over the past 30 days. Core Molding Technologies has a market cap of $95.2 million and is part of the consumer goods sector and consumer non-durables industry. Shares are down 5.53% year-to-date as of the close of trading on Wednesday.

Core Molding Technologies, Inc., together with its subsidiaries, manufactures sheet molding compounds (SMC) and molds fiberglass reinforced plastics. The company has a P/E ratio of 7.8. Currently, there are no analysts who rate Core Molding Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMT - FREE

TheStreet Quant Ratings rates Core Molding Technologies as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full Core Molding Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cell Therapeutics (CTIC) - FREE Research Report

Bianco James A, who is President and CEO at Cell Therapeutics, sold 318,169 shares at $0.55 on March 23, 2016. Following this transaction, the President and CEO owned 1.8 million shares meaning that the stake was reduced by 14.88% with the 318,169-share transaction.

The shares most recently traded at $3.01, up $2.46, or 81.74% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares bought: 934,623
  • 4-Week # shares sold: 35,000
  • 12-Week # shares bought: 934,623
  • 12-Week # shares sold: 180,000
  • 24-Week # shares bought: 934,623
  • 24-Week # shares sold: 660,000

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices